Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 194Sarcoma 24Gastrointestinal 22Lymphoid 18Genitourinary 18Myeloid 13Dermatologic 9Thoracic 8Head & Neck 8Other hematologic neoplasm 6Endocrine 5Breast 4NET 2Gynecologic 2Plasma cell 1Other solid neoplasm 1

Conditions

Advanced Solid Tumors 64Advanced Solid Tumor 54Solid Tumor 50Solid Tumors 40Mesothelioma 40Mesothelioma, Malignant 37Hematopoietic and Lymphatic System Neoplasm 21Solid Tumor, Adult 16Carcinoma, Non-Small-Cell Lung 15Melanoma 13Malignant Solid Neoplasm 13Ovarian Neoplasms 12Sarcoma 10Retinoblastoma 9Pancreatic Neoplasms 9Lung Neoplasms 8Advanced Malignant Solid Neoplasm 8Small Cell Lung Carcinoma 7Kidney Neoplasms 7Colorectal Neoplasms 7Cholangiocarcinoma 7Carcinoma, Renal Cell 7Advanced or Metastatic Solid Tumors 7Stomach Neoplasms 6Solid Tumours 6Carcinoma, Hepatocellular 6Advanced/Metastatic Solid Tumors 6Advanced Malignant Solid Tumor 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5

Interventions

LY2940680 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Other solid neoplasm × 90 days × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡